课题基金 / 基金详情

BETA BLOCKER EVALUATION OF SURVIVAL TRIAL

BETA BLOCKER EVALUATION OF SURVIVAL TRIAL
β 受体阻滞剂生存试验评估
批准号：
6303034
负责人：
WILLIAM J ROGERS
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6303034
关键词：
beta antiadrenergic agent clinical research combination chemotherapy congestive heart failure drug screening /evaluation heart disorder chemotherapy human mortality human subject human therapy evaluation placebos

项目摘要

项目成果

WILLIAM J ROGERS的其他基金

相似基金

相关文献

中文摘要
翻译
β受体阻滞剂生存评估试验（BEST）是一项NHLBI和
英文摘要
The Beta Blocker Evaluation of Survival Trial (BEST) is an NHLBI and VA-sponsored multicenter investigation assessing whether an investigational beta blocker, bucindolol, impacts on survival in patients with Class III-IV congestive heart failure and ejection fraction of 35% or less. The study goal is 2,800 patients. The study remains in its recruitment phase and approximately 2,100 patients have been recruited to date.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BARI 2D STUDY
BARI 2D STUDY
BYPASS ANGIOPLASTY REVASCULARIZATION INVESTIGATION 2 DIABETES (BARI 2D) STUDY
Bypass angioplasty revascularization invest. 2 diabetes
海外基金